Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Microarrays Aim for Center Stage

This article was originally published in Start Up

Executive Summary

Accepted in discovery, microarrays are paving the way for biomarker development and eventually, molecular diagnostics.

You may also be interested in...

Nanosphere Inc.

Gold nanoparticles studded with oligonucleotides form the basis of Nanosphere Inc.'s molecular detection systems. The company claims its lead product can rapidly detect SNPs from a blood sample without PCR and with minimal preparation. Nanosphere has no intentions of entering the discovery arena or of collecting the kinds or volumes of data typical for high-density microarrays: it will develop assays only for clinically validated biomarkers.

Spectral Genomics Inc.

Spectral Genomics Inc., aims to become one of the first, if not the first, to bring a diagnostic microarray through to FDA approval. Spectral belives its BAC clone arrays offer major advantages in detecting large scale chromosomal amplifications, deletions and rearrangements characteristic of cancers and many congenital defects. The speed and universality of the arrays make them potentially practical for low-cost, high-speed, and targeted diagnostic purposes.

Agilix Corp.

Mid-stage clinical trial data rarely provide an easy answer on whether to advance a compound into complex and costly pivotal studies. Agilix Corp. has stepped into that void to offer gene expression analysis services using its GenCompass-a microarry-based expression profiling system that provides a rapid whole genome comparison between test and control subjects, providing data even about as yet uncharacterized genes.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts